<DOC>
	<DOCNO>NCT00810667</DOCNO>
	<brief_summary>The objective study explore efficacy , safety cognitive property Lu AE58054 augmentation therapy risperidone patient schizophrenia .</brief_summary>
	<brief_title>Efficacy Study Exploring Effect Lu AE58054 Augmentation Therapy Patients With Schizophrenia</brief_title>
	<detailed_description>Lu AE58054 selective 5-HT6 antagonist currently investigate treatment condition cognitive impairment associate schizophrenia . Substantial experimental evidence suggest selective 5-HT6 receptor antagonist may effective treat cognitive deficit since show improve performance various animal model cognitive function know enhance cholinergic glutaminergic neuronal function . Lu AE58054 investigate healthy volunteer patient schizophrenia , generally well tolerated benign side-effect profile . Moreover , safety concern issue identify date . The study design provide data efficacy , safety cognitive property Lu AE58054 augmentation therapy risperidone patient schizophrenia . Efficacy assess patient stable phase illness , predefined minimum maximum level symptom allow include study . Patients randomly assign receive either investigational medicinal product ( IMP ) placebo add-on therapy exist risperidone treatment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Primary diagnosis schizophrenia Man woman , age 1865 Patient optimise dose risperidone ( within 48 mg/day ) treatment schizophrenia minimum 4 week prior screen The patient PANSS total score 70 100 ( extreme include ) screen Primary psychiatric diagnosis schizophrenia Acute exacerbation require hospitalisation within last 3 month Clinically significant extrapyramidal symptom Clinically significant cardiovascular disease , congestive heart failure , cardiac hypertrophy , arrhythmia bradycardia Significant ECG abnormality In concurrent treatment drug inhibit P450 enzyme system CYP2D6 CYP Isozymes Failed respond adequate course treatment risperidone Treated antipsychotic risperidone within 4 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>BACS</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Augmentation therapy</keyword>
	<keyword>Add-on therapy</keyword>
	<keyword>Lu AE58054</keyword>
</DOC>